Healthcare • Biotechnology
EODHD (TTM) · as of Oct 13, 2026
End-of-day close from stored market data, not a live quote.
Sign in to see your position size
We’ll show you if INBX is in your portfolio and how much it contributes.
Sign inLoading market dates
No upcoming ex-dividend date announced
No 8-K filings in the last 30 days.
25 top institutions tracked
Last 13F trend: distributing (light)
Unlock crowding heatmapUnlock filer discoverySentiment: bullish
Last trade: buy 16 days ago
Red flags: 4
162 filers reported a long position in INBX for Q2 2026. 13-F holdings are filed up to 45 days after the quarter ends.
| Holder | Value | Shares | Shares vs Q1 2026 |
|---|---|---|---|
| MORGAN STANLEY | $123.9M | 1.3M | +3.6% |
| PERCEPTIVE ADVISORS LLC | $123M | 1.3M | -10% |
| Sanofi | $109.7M | 1.2M | Unchanged |
| VIKING GLOBAL INVESTORS LP | $106.5M | 1.1M | -21.8% |
| HighTower Advisors, LLC | $82.5M | 870.6K | 0% |
| BANK OF AMERICA CORP /DE/ | $79.7M | 841.1K | +2,473.6% |
| BlackRock, Inc. | $78.3M | 826K | +3.4% |
| Schonfeld Strategic Advisors LLC | $66.1M | 697.6K | +173.7% |
| STATE STREET CORP | $60.7M | 640.5K | +16.3% |
| VANGUARD CAPITAL MANAGEMENT LLC | $46.7M | 492.5K | +1.2% |
Unlock detailed insider transactions, institutional holder changes, factor exposures, and personalized alerts. Start free with your own portfolio.